U.S. District Court Issues Decision Regarding CINVANTI® Patents
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Heron: Near The Bottom Of A Trading Range Despite Positives
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of “Hold” from Analysts
Congress Park Capital LLC Acquires 621,908 Shares of Heron Therapeutics, Inc. $HRTX
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives $4.50 Average Price Target from Brokerages
Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Heron (HRTX) Q2 Acute Care Jumps 56%
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025
Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
Best Momentum Stocks to Buy for April 22nd